Question special
Trainee ST 4-8

While you clearly set out to test nirsevimab in a population who would not usually be treated with palivizumab as a clinician I would have found it very helpful to know how this treatment compares to an existing treatment (particularly since the main barrier to using palivizumab in this group is not doubts about efficacy but rather about cost effectiveness). Thanks!